Baxter Other Non-Current Liabilities 2010-2024 | BAX
Baxter other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Baxter other non-current liabilities for the quarter ending September 30, 2024 were $1.263B, a 28.97% decline year-over-year.
- Baxter other non-current liabilities for 2023 were $1.737B, a 6.01% decline from 2022.
- Baxter other non-current liabilities for 2022 were $1.848B, a 25.87% decline from 2021.
- Baxter other non-current liabilities for 2021 were $2.493B, a 49.01% increase from 2020.
| Baxter Annual Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2023 | $1,737 |
| 2022 | $1,848 |
| 2021 | $2,493 |
| 2020 | $1,673 |
| 2019 | $1,732 |
| 2018 | $1,559 |
| 2017 | $1,665 |
| 2016 | $1,743 |
| 2015 | $2,425 |
| 2014 | $4,614 |
| 2013 | $3,364 |
| 2012 | $3,073 |
| 2011 | $2,639 |
| 2010 | $2,289 |
| 2009 | $2,030 |
| Baxter Quarterly Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2024-09-30 | $1,263 |
| 2024-06-30 | $1,598 |
| 2024-03-31 | $1,652 |
| 2023-12-31 | $1,400 |
| 2023-09-30 | $1,778 |
| 2023-06-30 | $1,622 |
| 2023-03-31 | $1,854 |
| 2022-12-31 | $1,848 |
| 2022-09-30 | $2,071 |
| 2022-06-30 | $2,264 |
| 2022-03-31 | $2,434 |
| 2021-12-31 | $2,493 |
| 2021-09-30 | $1,621 |
| 2021-06-30 | $1,624 |
| 2021-03-31 | $1,636 |
| 2020-12-31 | $1,673 |
| 2020-09-30 | $1,824 |
| 2020-06-30 | $1,882 |
| 2020-03-31 | $1,827 |
| 2019-12-31 | $1,732 |
| 2019-09-30 | $1,514 |
| 2019-06-30 | $1,464 |
| 2019-03-31 | $1,483 |
| 2018-12-31 | $1,559 |
| 2018-09-30 | $1,545 |
| 2018-06-30 | $1,585 |
| 2018-03-31 | $1,605 |
| 2017-12-31 | $1,665 |
| 2017-09-30 | $1,925 |
| 2017-06-30 | $1,786 |
| 2017-03-31 | $1,762 |
| 2016-12-31 | $1,743 |
| 2016-09-30 | $1,691 |
| 2016-06-30 | $1,655 |
| 2016-03-31 | $2,439 |
| 2015-12-31 | $2,425 |
| 2015-09-30 | $2,555 |
| 2015-06-30 | $3,628 |
| 2015-03-31 | $3,819 |
| 2014-12-31 | $4,614 |
| 2014-09-30 | $3,394 |
| 2014-06-30 | $3,619 |
| 2014-03-31 | $3,406 |
| 2013-12-31 | $3,364 |
| 2013-09-30 | $3,856 |
| 2013-06-30 | $3,296 |
| 2013-03-31 | $3,382 |
| 2012-12-31 | $3,073 |
| 2012-09-30 | $2,563 |
| 2012-06-30 | $2,532 |
| 2012-03-31 | $2,552 |
| 2011-12-31 | $2,639 |
| 2011-09-30 | $2,041 |
| 2011-06-30 | $2,088 |
| 2011-03-31 | $2,202 |
| 2010-12-31 | $2,289 |
| 2010-09-30 | $2,241 |
| 2010-06-30 | $2,149 |
| 2010-03-31 | $2,167 |
| 2009-12-31 | $2,030 |
| 2009-09-30 | $2,039 |
| 2009-06-30 | $1,981 |
| 2009-03-31 | $1,998 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $16.737B | $14.813B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $221.767B | 27.38 |
| Boston Scientific (BSX) | United States | $151.377B | 43.52 |
| Stryker (SYK) | United States | $149.082B | 32.08 |
| EssilorLuxottica (ESLOY) | France | $125.055B | 0.00 |
| Medtronic (MDT) | Ireland | $117.214B | 17.41 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.950B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.139B | 28.03 |
| GE HealthCare Technologies (GEHC) | United States | $40.136B | 20.82 |
| ResMed (RMD) | United States | $37.119B | 30.50 |
| Terumo (TRUMY) | Japan | $28.886B | 41.07 |
| Koninklijke Philips (PHG) | Netherlands | $25.642B | 19.63 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.107B | 14.07 |
| Insulet (PODD) | United States | $19.438B | 77.40 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.065B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.084B | 40.57 |
| Sunny Optical Technology (SNPTF) | China | $9.976B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.966B | 33.87 |
| Demant (WILYY) | Denmark | $8.735B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.433B | 14.95 |
| ICU Medical (ICUI) | United States | $4.121B | 39.23 |
| Prestige Consumer Healthcare (PBH) | United States | $3.893B | 19.36 |
| Envista Holdings (NVST) | United States | $3.678B | 27.40 |
| Haemonetics (HAE) | United States | $3.430B | 16.74 |
| Perrigo (PRGO) | Ireland | $3.366B | 9.91 |
| GN Store Nord (GNNDY) | Denmark | $3.027B | 19.41 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.989B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.927B | 18.84 |
| Neogen (NEOG) | United States | $2.495B | 28.75 |
| LeMaitre Vascular (LMAT) | United States | $2.247B | 54.60 |
| AtriCure (ATRC) | United States | $2.067B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.464B | 25.63 |
| InMode (INMD) | Israel | $1.462B | 8.79 |
| AdaptHealth (AHCO) | United States | $1.430B | 10.22 |
| BioLife Solutions (BLFS) | United States | $1.313B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.270B | 0.00 |
| Owens & Minor (OMI) | United States | $1.150B | 8.99 |
| Evolus (EOLS) | United States | $0.922B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.887B | 15.64 |
| CeriBell (CBLL) | United States | $0.833B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.830B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.649B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.561B | 24.73 |
| Surmodics (SRDX) | United States | $0.511B | 0.00 |
| Omeros (OMER) | United States | $0.502B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.432B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.429B | 0.00 |
| Valneva SE (VALN) | France | $0.412B | 0.00 |
| ZimVie (ZIMV) | United States | $0.401B | 33.77 |
| Quanterix (QTRX) | United States | $0.370B | 0.00 |
| Cerus (CERS) | United States | $0.360B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.322B | 30.67 |
| Sanara MedTech (SMTI) | United States | $0.317B | 0.00 |
| Biote (BTMD) | United States | $0.309B | 6.76 |
| OraSure Technologies (OSUR) | United States | $0.291B | 19.50 |
| Canopy Growth (CGC) | Canada | $0.265B | 0.00 |
| Zynex (ZYXI) | United States | $0.263B | 55.13 |
| High Tide (HITI) | Canada | $0.239B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.233B | 3.28 |
| Utah Medical Products (UTMD) | United States | $0.208B | 15.52 |
| Aurora Cannabis (ACB) | Canada | $0.203B | 0.00 |
| Brainsway (BWAY) | Israel | $0.197B | 104.70 |
| MacroGenics (MGNX) | United States | $0.190B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.189B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.154B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.145B | 18.27 |
| Quipt Home Medical (QIPT) | United States | $0.135B | 0.00 |
| Jin Medical (ZJYL) | China | $0.125B | 0.00 |
| Fonar (FONR) | United States | $0.102B | 11.54 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Veru (VERU) | United States | $0.089B | 0.00 |
| InterCure (INCR) | Israel | $0.077B | 0.00 |
| Exagen (XGN) | United States | $0.072B | 0.00 |
| INLIF (INLF) | $0.071B | 0.00 | |
| Rockwell Medical (RMTI) | United States | $0.066B | 34.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| Apyx Medical (APYX) | United States | $0.055B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.055B | 0.00 |
| Modular Medical (MODD) | United States | $0.051B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.051B | 0.00 |
| United-Guardian (UG) | United States | $0.050B | 14.35 |
| ImmuCell (ICCC) | United States | $0.048B | 0.00 |
| Safety Shot (SHOT) | United States | $0.031B | 0.00 |
| Nephros (NEPH) | United States | $0.018B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.015B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.001B | 0.00 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |